Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05606484
Other study ID # TFM.MMC.EJPP.EMO.220221
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 9, 2023
Est. completion date December 1, 2023

Study information

Verified date February 2023
Source Universidad Miguel Hernandez de Elche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background. An increase in inflammatory biomarkers is associated with impaired kidney function and increased cardiovascular risk and mortality. Physical exercise has been shown to improve the functional capacity and inflammatory status of patients undergoing hemodialysis (HD) treatment, increasing their health-related quality of life. Virtual reality (VR) is an effective and safe tool to increase patient adherence to the exercise program, however, there are very few studies that analyze its effect on the functional capacity of patients with chronic kidney disease (CKD) in HD and none analyze its effect on the inflammatory state of these patients, which justifies the performance of this study. Methods. Eighty patients with CKD on HD treatment will be randomly assigned into two groups, one of them will perform an intradialysis exercise program with non-immersive VR (intervention group; n=40), and the other will exercise with a static pedal (control group; n). =40). The functional capacity of the patients and their inflammatory and psychological status, as well as their exercise adherende, will be analyzed before and after exercise programs.


Description:

Description of the intervention The exercise program will last for 12 weeks. Randomly, half of the patients will be instructed to - Control Group (CG): They will be instructed to exercise with a static pedal (control group) and the other half will be instructed to carry out the intradialysis non-immersive virtual reality exercise program. - Intervention Group (IG): Will perform an intradialysis physical exercise program with non-immersive virtual reality during the first two hours of hemodialysis treatment (n = 40). - Control Group (CG): They will exercise with a static pedal (n = 40). Exercise program The direction and supervision of the exercise programs will be the responsibility of the nursing staff of the Hemodialysis Unit and several physiotherapists of the Rehabilitation Unit of the General University Hospital of Alicante Doctor Balmis, the nursing staff being in charge of directing and supervising the intradialysis exercise program. Prior to the beginning of the intervention, said personnel will receive exhaustive training on the characteristics of the exercise program and on how to carry it out in an optimal way. In this training they will be instructed on how to execute each of the exercises in the program with virtual reality. During the two weeks prior to the intervention, a "first contact" period will be carried out, during which the nursing staff will implement the virtual reality intradialis exercise program as a test, so that they can familiarize themselves with the material necessary to exercise, as well as resolve any doubts that may arise. This trial period will be supervised by the physiotherapist in charge of giving them the training. On the other hand, to improve adherence to exercise by patients and avoid losses throughout the program, all the staff in charge of directing and supervising the exercise will receive a training session by a psychologist specialized in managing barriers in special populations during exercise, with the aim of developing strategies to address these barriers during the intervention period. The exercise program will have a duration of 12 weeks, with a frequency of 3 exercise sessions per week, these being of a progressive duration according to the patient's capacity (EEP 13-15), until reaching 30 minutes per session, and performed during the first two hours of HD treatment. Before and after each exercise session, heart rate and blood pressure will be recorded. Patients will be instructed to perform the exercise independently or with minimal assistance. The non-immersive virtual reality exercise program is described below: - Intervention Group (IG): Participants assigned to this group will start with a 5-minute warm-up session and then perform a virtual reality exercise session for up to a maximum of 30 minutes, depending on the rate of perceived exertion that should be felt between "somewhat hard" and "hard" (13-15 out of 20 in EEP). The intensity will progress by increasing the number of exercise series (each lasting 3 minutes) and may vary between 1 and 10 series, depending on the patient's capacity, taking a 1-minute break between each series. The hemodialysis session may be carried out simultaneously with the exercise, since the work will focus on the lower limbs. An adapted version of ACT (Treasure Hunt) will be used for the VR program. ACT is a non-immersive virtual reality system designed with a playful scheme. For the participants, the system is an intradialysis virtual reality game, which makes dialysis sessions more enjoyable. In ACT, the subject tries to hit a series of targets (avoiding obstacles) by moving the leg. The difficulty in ACT is graduated according to the characteristics of the participants, who will be able to change the leg during the game when they feel tired. The general hardware setup consists of a standard computer, a television (commonly found in HD units), and a Ms Kinect® motion tracking system. At the beginning of the session, the therapists define the VR intervention for the session using a management tool, adding different rest periods and configuring their duration. The difficulty level of the exercise will also be set at startup, and therapists will be able to program the system to automatically increase or decrease the difficulty level depending on the participant's performance. Before their first session, each participant will receive instructions on the general use of the system and a test session will take place. At the end of the program, participants will end the session with another 5 minutes of gentle stretching. Control group (CG): The participants in this group will exercise with a static pedal, exercising the same muscle groups as the VR group. They will perform the exercise at the same time as the VR group, during the first two hours of hemodialysis, with a duration of 30 minutes each session, performing 3 weekly sessions at a perceived exertion intensity of 12-15 (something hard-hard) in the Borg scale. The patients will be blind, being distributed in the hemodialysis room so that in one area there are the patients who exercise with VR and in the other the patients who exercise with a static pedal.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria: - Patients with CKF in a stable clinical situation who have been on HD treatment for at least 3 months. Exclusion criteria: - Had a myocardial infarction in the 6 months before the start of the study - Suffered unstable angina at rest or during exercise - Have cerebrovascular diseases (such as transient ischemia or stroke) - Present amputation of lower limbs above the knee without prothesis - Present a musculoskeletal or respiratory pathology likely to worsen with exercise - Present an inability to carry out functional assessment tests - Present visual or cognitive impairments that affect the ability to use the VR equipment or understand the VR exercise

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise with non-immersive virtual reality
Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
Exercise with a static pedal
Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Universidad Miguel Hernandez de Elche European University of Madrid

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Interleuquine 6 (IL-6) (pg/ml) Inflammatoy marker Change from Baseline IL-6 at 12 weeks
Primary Change of Tumoral Necrosis Factor-alpha (TNF-alpha) (pg/ml) Inflammatoy marker Change from Baseline TNF-a at 12 weeks
Primary Change of C Reactive Protein (CRP) (mg/L) Inflammatoy marker Change from Baseline CRP at 12 weeks
Primary Change of Intercellular Adhesion Molecule 1 (ICAM 1) (ng/ml) Inflammatoy marker Change from Baseline ICAM 1 at 12 weeks
Primary Change of Vascular cell adhesion protein 1 (VCAM 1) (ng/ml) Inflammatoy marker Change from Baseline VCAM 1 at 12 weeks
Secondary Assessment of the functional capacity of patients: Short Physical Performance Battery (SPPB) Mesure dependency, institutionalization, hospitalization and mortality. Score ranges from 1 to 12 points baseline and up to 12 weeks
Secondary Assessment of the functional capacity of patients: 10 Sit To Stand Test (10 STS). Seconds it takes for the patient to get up and sit down 10 times baseline and up to 12 weeks
Secondary Assessment of the functional capacity of patients: 60 Sit To Stand Test (60 STS). Number of times the patient gets up and sits down during 60 seconds baseline and up to 12 weeks
Secondary Assessment of the functional capacity of patients: 6 minute walk test (6MWT) Meters that a patient is able to walk for 6 minutes baseline and up to 12 weeks
Secondary Psychological assessment of patients: Multidimensional Questionnaire of Adaptation to the Disease for Renal Patients on Dialysis It consists of two phases: Phase A and Phase B. The Phase A, which includes 12 items, collects all the information from the clinical history of the patient. This phase includes two areas "Data Doctors" and "Previous Psychopathological History". Phase B, which includes 51 items, it is made up of nine areas that make up the evaluation of the patient. This phase includes the following areas: "Sociodemographic data" (6 items), "Information",(9 items), "Medication and diet" (3 items), "Social support" (4 items), "State of encouragement" (2 items), "Personal resources, coping and resilience" (8 items), "Learning and perceived changes" (5 items), "Spirituality" (2 items) and "Care planning" (2 items). The questions have four formats of response; three of them closed in nature (dichotomous responses, nominal categorical, and 10-point Likert-type scales), and one open and qualitative. An increase in the scale score is positive. A change a < 0.05 is considered statistically significant. baseline and up to 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT02922361 - Spending and Outcomes for Complex Medicare Advantage Patients
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis Phase 4
Not yet recruiting NCT01674660 - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients N/A
Not yet recruiting NCT01157260 - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Phase 4
Completed NCT01209403 - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Phase 4
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00382044 - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients N/A
Completed NCT00226902 - Vascular Reactivity in Kidney Disease Patients N/A
Recruiting NCT00235287 - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Phase 4
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00006297 - Risk Factors for CV Disease in a Dialysis Cohort N/A